RhumbLine Advisers
KALV

RhumbLine Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

RhumbLine Advisers’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$956K Buy
47,469
+78
+0.2% +$1.26K ﹤0.01% 2217
2025
Q4 		$765K Sell
47,391
-5,407
-10% -$71.6K ﹤0.01% 2381
2025
Q3 		$643K Sell
52,798
-1,578
-3% -$21.8K ﹤0.01% 2523
2025
Q2 		$615K Buy
54,376
+1,458
+3% +$17.8K ﹤0.01% 2551
2025
Q1 		$611K Buy
52,918
+1,762
+3% +$18K ﹤0.01% 2444
2024
Q4 		$433K Buy
51,156
+877
+2% +$9.08K ﹤0.01% 2764
2024
Q3 		$582K Sell
50,279
-2,949
-6% -$37.1K ﹤0.01% 2598
2024
Q2 		$627K Buy
53,228
+5,908
+12% +$68.9K ﹤0.01% 2511
2024
Q1 		$561K Buy
47,320
+1,959
+4% +$26.1K ﹤0.01% 2602
2023
Q4 		$556K Buy
45,361
+3,466
+8% +$31.5K ﹤0.01% 2604
2023
Q3 		$403K Buy
41,895
+164
+0.4% +$1.68K ﹤0.01% 2736
2023
Q2 		$376K Buy
41,731
+2,909
+7% +$26.8K ﹤0.01% 2876
2023
Q1 		$305K Buy
38,822
+1,237
+3% +$9.23K ﹤0.01% 2607
2022
Q4 		$254K Buy
37,585
+72
+0.2% +$386 ﹤0.01% 2726
2022
Q3 		$544K Buy
37,513
+2,844
+8% +$39.8K ﹤0.01% 2462
2022
Q2 		$341K Buy
34,669
+12,519
+57% +$138K ﹤0.01% 2690
2022
Q1 		$326K Buy
22,150
+3,100
+16% +$44.5K ﹤0.01% 2613
2021
Q4 		$252K Sell
19,050
-11
-0.1% -$175 ﹤0.01% 2763
2021
Q3 		$333K Buy
19,061
+897
+5% +$18.2K ﹤0.01% 2725
2021
Q2 		$435K Sell
18,164
-5,013
-22% -$131K ﹤0.01% 2630
2021
Q1 		$595K Buy
23,177
+4,188
+22% +$110K ﹤0.01% 2407
2020
Q4 		$361K Buy
18,989
+3,236
+21% +$55.5K ﹤0.01% 2587
2020
Q3 		$198K Sell
15,753
-1,897
-11% -$23.7K ﹤0.01% 2692
2020
Q2 		$214K Buy
17,650
+6,923
+65% +$73.6K ﹤0.01% 2736
2020
Q1 		$82K Sell
10,727
-150
-1% -$2.02K ﹤0.01% 2811
2019
Q4 		$194K Buy
10,877
+238
+2% +$3.11K ﹤0.01% 2757
2019
Q3 		$123K Sell
10,639
-80
-0.7% -$1.29K ﹤0.01% 2853
2019
Q2 		$237K Buy
+10,719
New +$251K ﹤0.01% 2719
2016
Q2 		– Sell
-973
Closed -$9K – 3005
2016
Q1 		$9K Hold
973
– – ﹤0.01% 2988
2015
Q4 		$49K Buy
+973
New +$50.9K ﹤0.01% 3003

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's KALV Position: Q1 2026 in Review

RhumbLine Advisers increased its KalVista Pharmaceuticals (KALV) stake by 0.16% in Q1 2026, buying an estimated $1.26K and bringing the position to 47,469 shares worth $956K. The position accounts for ﹤0.01% of the portfolio, ranked #2217.

RhumbLine Advisers first reported a position in KALV in Q4 2015 and has held it in 30 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • RhumbLine Advisers held 47,469 shares of KalVista Pharmaceuticals worth $956K as of Q1 2026.
  • RhumbLine Advisers bought 78 KalVista Pharmaceuticals shares in Q1 2026, an estimated $1.26K.
  • KalVista Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2217 holding.
  • RhumbLine Advisers first reported a position in KalVista Pharmaceuticals in Q4 2015 and has held it in 30 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.